Timothy Mant

3.1k citations

42 papers · 1.6k indexed · 1 hit paper · h-index 20

Molecular Biology
Surgery top 10%
Genetics top 5%
Hematology top 5%
Cardiology and Cardiovascular Medicine top 10%

Co-authors: James M. Ritter Joseph Chiesa Kevin Fitzgerald Jessica E. Sutherland Maria Frank-Kamenetsky Valerie A. Clausen Amy Simon Verena Karsten
Topics: Hemoglobinopathies and Related Disorders (10 papers)Lipoproteins and Cardiovascular Health (3 papers)Myeloproliferative Neoplasms: Diagnosis and Treatment (3 papers)
Cited by: Genetics Anesthesiology and Pain Medicine Hematology
Journals: The Lancet Blood The American Journal of Medicine
Partner nations: United Kingdom United States Australia

In The Last Decade

Timothy Mant

42 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial

2013 467 citations Renta Hutabarat, Timothy Mant et al. profile →

Peers

Countries citing papers authored by Timothy Mant

Since Specialization

Citations

This map shows the geographic impact of Timothy Mant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Timothy Mant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Timothy Mant more than expected).

Fields of papers citing papers by Timothy Mant

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Timothy Mant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Timothy Mant. The network helps show where Timothy Mant may publish in the future.

Co-authorship network of co-authors of Timothy Mant

This figure shows the co-authorship network connecting the top 25 collaborators of Timothy Mant. A scholar is included among the top collaborators of Timothy Mant based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Timothy Mant. Timothy Mant is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease 2019 ·Blood ·Jo Howard,Claire Hemmaway,Paul Telfer,D. Mark Layton,John B. Porter,Moji Awogbade,Timothy Mant,Daniel D. Gretler,Kobina Dufu,Athiwat Hutchaleelaha,Mira Patel,(unknown),(unknown),(unknown),Margaret Tonda,Joshua Lehrer‐Graiwer	84
2	Group II metabotropic glutamate receptor agonist prodrugs LY2979165 and LY2140023 attenuate the functional imaging response to ketamine in healthy subjects 2018 ·Psychopharmacology ·Mitul A. Mehta,Anne Schmechtig,(unknown),Juliet McColm,Kimberley Jackson,Claire Brittain,Sitra Tauscher‐Wisniewski,Bruce J. Kinon,Paul D. Morrison,Thomas Pollak,Timothy Mant,Steven Williams,Adam J. Schwarz	31
3	Safety and patient response as indicated by biomarker changes to binding immunoglobulin protein in the phase I/IIA RAGULA clinical trial in rheumatoid arthritis 2016 ·Lara D. Veeken ·Bruce Kirkham,(unknown),Christopher Hall,Toby Garrood,Timothy Mant,Elizabeth D. Allen,Alexandra Vincent,Joana C. Vasconcelos,A Toby Prevost,G S Panayi,Valerie Corrigall	34
4	Long-Term Dosing in Sickle Cell Disease Subjects with GBT440, a Novel HbS Polymerization Inhibitor 2016 ·Blood ·(unknown),Jo Howard,Claire Hemmaway,Moji Awogbade,Paul Telfer,Mark Layton,John B. Porter,Timothy Mant,Kobina Dufu,Athiwat Hutchaleelaha,Donna Oksenberg,Mira Patel,Margaret Tonda,Kenneth R. Bridges,Eleanor L. Ramos	11
5	GBT440, a Potent Anti-Sickling Hemoglobin Modifier Reduces Hemolysis, Improves Anemia and Nearly Eliminates Sickle Cells in Peripheral Blood of Patients with Sickle Cell Disease 2015 ·Blood ·(unknown),Jo Howard,Claire Hemmaway,Moji Awogbade,Paul Telfer,Mark Layton,Timothy Mant,Kobina Dufu,Athiwat Hutchaleelaha,(unknown),Donna Oksenberg,Mira Patel,Eleanor L. Ramos	20
6	ALN-TTR, an RNAI therapeutic for the treatment of transthyretin amyloidosis 2011 ·Nucleic Acid Therapeutics ·Dinah W.Y. Sah,Qingmin Chen,(unknown),(unknown),(unknown),Anthony Rossomando,Lubomir V. Nechev,Maria João Saraiva,Teresa Coelho,Ole B. Suhr,David Adams,Pierre Lozeron,Philip N. Hawkins,Timothy Mant,Renta Hutabarat,Rick Falzone,Jeff Cehelsky,(unknown),Akshay Vaishnaw,Jared Gollob	1
7	Effects of a cytokine inhibitor, JTE-607, on the response to endotoxin in healthy human volunteers 2011 ·International Immunopharmacology ·(unknown),Timothy Mant,Elizabeth D. Allen,(unknown),(unknown),Stipo Jurčević	5
8	Pharmacokinetics, Tolerability, and Safety of ACP‐103 Following Single or Multiple Oral Dose Administration in Healthy Volunteers 2007 ·The Journal of Clinical Pharmacology ·Kimberly E. Vanover,(unknown),(unknown),Timothy Mant,Daniël P. van Kammen,Robert E. Davis,David M. Weiner	30
9	The Effects of Food on the Pharmacokinetics of a Formulated ACP‐103 Tablet in Healthy Volunteers 2007 ·The Journal of Clinical Pharmacology ·Kimberly E. Vanover,(unknown),(unknown),Timothy Mant,Daniël P. van Kammen,Robert E. Davis,David M. Weiner	14
10	Pharmacokinetics and safety assessments of high‐dose and 4‐week treatment with S‐3304, a novel matrix metalloproteinase inhibitor, in healthy volunteers 2006 ·British Journal of Clinical Pharmacology ·Timothy Mant,(unknown),Dipti Amin,(unknown),Yoshikazu Kambayashi,Yoshitaka Yano,Kazushige Tanaka,(unknown)	5
11	Phase I Trial of ISIS 104838, a 2′-Methoxyethyl Modified Antisense Oligonucleotide Targeting Tumor Necrosis Factor-α 2002 ·Journal of Pharmacology and Experimental Therapeutics ·K. Lea Sewell,Richard S. Geary,Brenda F. Baker,(unknown),Timothy Mant,Rosie Z. Yu,Joseph A. Tami,F. Andrew Dorr	99
12	Absence of Interaction of Fondaparinux Sodium with Digoxin in Healthy Volunteers 2002 ·Clinical Pharmacokinetics ·Timothy Mant,(unknown),Céline Ollier,(unknown),(unknown)	21
13	Effect of dexmedetomidine on propofol requirements in healthy subjects 2001 ·Journal of Pharmaceutical Sciences ·Sandeep Dutta,Michael D. Karol,Theodora Cohen,(unknown),Timothy Mant	78
14	Clinical Safety of SonoVue™, a New Contrast Agent for Ultrasound Imaging, in Healthy Volunteers and in Patients with Chronic Obstructive Pulmonary Disease 2001 ·Investigative Radiology ·Daniela Bokor,John B. Chambers,P. J. Rees,Timothy Mant,Franco Luzzani,Alberto Spinazzi	95
15	Plasma Uridine as well as Uric Acid is Elevated Following Fructose Loading 1998 ·Advances in experimental medicine and biology ·P. M. Davies,H. Anne Simmonds,Brett C. Singer,Timothy Mant,Elizabeth M. Allen,Artemios B. Vassos,Neil Hounslow	4
16	The tolerance and pharmacokinetics of clinafloxacin (CI-960) in healthy subjects 1996 ·Journal of Antimicrobial Chemotherapy ·(unknown),(unknown),Timothy Mant,C. L. Webb,Artemios B. Vassos	24
17	Nonlinear Multiple-Dose Pharmacokinetics of the Dopamine Reuptake Inhibitor Vanoxerine 1993 ·Journal of Pharmaceutical Sciences ·Steen H. Ingwersen,(unknown),Timothy Mant,David Edwards	10
18	CLINICAL IMPRESSIONS AND CARDIORESPIRATORY EFFECTS OF A NEW FLUORINATED INHALATION ANAESTHETIC, DESFLURANE (1–653), IN VOLUNTEERS 1990 ·British Journal of Anaesthesia ·Ronald M. Jones,J. N. Cashman,Timothy Mant	41
19	Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study. 1989 ·BMJ ·Marius Rademaker,E D Cooke,N. E. Almond,(unknown),Roy E. Smith,Timothy Mant,J.D. Kirby	155
20	ABC of poisoning. Respiratory drugs. 1984 ·BMJ ·Timothy Mant,(unknown),(unknown)	3

About Timothy Mant

Timothy Mant is a scholar working on Genetics, Anesthesiology and Pain Medicine and Hematology, having authored 42 papers that have together received 1.6k indexed citations. Recurring topics across this work include Hemoglobinopathies and Related Disorders (10 papers), Lipoproteins and Cardiovascular Health (3 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (3 papers). The work is most often cited by research in Genetics (256 citations), Anesthesiology and Pain Medicine (124 citations) and Hematology (214 citations). Timothy Mant has collaborated with scholars based in United Kingdom, United States and Australia. Frequent co-authors include James M. Ritter, Joseph Chiesa, Kevin Fitzgerald, Jessica E. Sutherland, Maria Frank-Kamenetsky, Valerie A. Clausen, Amy Simon, Verena Karsten, Renta Hutabarat and Akshay Vaishnaw. Their work appears in journals such as The Lancet, Blood and The American Journal of Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact